PMID- 31766561
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 12
DP  - 2019 Nov 21
TI  - ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical 
      Evaluation Based on In Silico and In Vitro Data.
LID - 10.3390/cancers11121840 [doi]
LID - 1840
AB  - : Anilin actin binding protein (ANLN) and transducing-like enhancer protein 2 
      (TLE2) are associated with cancer patient survival and progression. The impact of 
      their gene expression on progression-free survival (PFS) of patients with muscle 
      invasive bladder cancer (MIBC) treated with radical cystectomy (RC) and subtype 
      association has not yet been investigated. qRT-PCR was used to measure the 
      transcript levels of ANLN and TLE2 in the Mannheim cohort, and validated in 
      silico by The Cancer Genome Atlas (TCGA) cohort. Uni- and multivariate Cox 
      regression analyses identified predictors for disease-specific survival (DSS) and 
      overall survival (OS). In the Mannheim cohort, tumors with high ANLN expression 
      were associated with lower OS and DSS, while high TLE2 expression was associated 
      with a favorable OS. The TCGA cohort confirmed that high ANLN and low TLE2 
      expression was associated with shorter OS and disease-free survival (DFS). In 
      both cohorts, multivariate analyses showed ANLN and TLE2 expression as 
      independent outcome predictors. Furthermore, ANLN was more highly expressed in 
      cell lines and patients with the basal subtype, while TLE2 expression was higher 
      in cell lines and patients with the luminal subtype. ANLN and TLE2 are promising 
      biomarkers for individualized bladder cancer therapy including cancer 
      subclassification and informed MIBC prognosis.
FAU - Wu, Sheng
AU  - Wu S
AD  - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of 
      Heidelberg, 68167 Mannheim, Germany.
FAU - Nitschke, Katja
AU  - Nitschke K
AD  - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of 
      Heidelberg, 68167 Mannheim, Germany.
FAU - Heinkele, Jakob
AU  - Heinkele J
AD  - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of 
      Heidelberg, 68167 Mannheim, Germany.
FAU - Weis, Cleo-Aron
AU  - Weis CA
AD  - Institute of Pathology, Medical Faculty Mannheim, University of Heidelberg, 68167 
      Mannheim, Germany.
FAU - Worst, Thomas Stefan
AU  - Worst TS
AD  - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of 
      Heidelberg, 68167 Mannheim, Germany.
FAU - Eckstein, Markus
AU  - Eckstein M
AD  - Institute of Pathology, University Hospital Erlangen, 
      Friedrich-Alexander-University Erlangen-Nurnberg, 91052 Erlangen, Germany.
FAU - Porubsky, Stefan
AU  - Porubsky S
AD  - Institute of Pathology, Medical Faculty Mannheim, University of Heidelberg, 68167 
      Mannheim, Germany.
FAU - Erben, Philipp
AU  - Erben P
AD  - Department of Urology and Urosurgery, Medical Faculty Mannheim, University of 
      Heidelberg, 68167 Mannheim, Germany.
LA  - eng
PT  - Journal Article
DEP - 20191121
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6966660
OTO - NOTNLM
OT  - biomarker
OT  - molecular subtype
OT  - muscle invasive bladder cancer
OT  - prognosis
COIS- The authors declare no conflicts of interest.
EDAT- 2019/11/27 06:00
MHDA- 2019/11/27 06:01
PMCR- 2019/11/21
CRDT- 2019/11/27 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2019/11/15 00:00 [revised]
PHST- 2019/11/19 00:00 [accepted]
PHST- 2019/11/27 06:00 [entrez]
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2019/11/27 06:01 [medline]
PHST- 2019/11/21 00:00 [pmc-release]
AID - cancers11121840 [pii]
AID - cancers-11-01840 [pii]
AID - 10.3390/cancers11121840 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Nov 21;11(12):1840. doi: 10.3390/cancers11121840.